{"schema_version":"secwatch.filing_event.v1","accession":"0001699350-26-000033","form_type":"8-K","ticker":"SI","cik":"0001699350","company_name":"SHOULDER INNOVATIONS, INC.","filed_at":"2026-05-13T20:08:18+00:00","discovered_at":"2026-05-13T20:09:00.298595+00:00","generated_at":"2026-05-13T20:10:17.763317+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Shoulder Innovations Q1 revenue up 65% to $16.7M, raises FY2026 guidance to $65-68M","bullets":["Net revenue $16.7M (+65% YoY); implant systems sold 2,184 (+51%); gross margin 77.7%.","Raised FY2026 net revenue guidance to $65-68M from $62-65M, representing 37-44% YoY growth.","Operating loss $9.0M, net loss $8.4M; adjusted EBITDA loss $7.0M; cash and marketable securities $108.5M.","Full commercial launch of InSet I-135RFX Humeral Stem after FDA clearance for additional fracture indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001699350-26-000033","json":"https://secwatch.observer/filing/0001699350-26-000033.json","markdown":"https://secwatch.observer/filing/0001699350-26-000033.md","text":"https://secwatch.observer/filing/0001699350-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699350/000169935026000033/0001699350-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699350/000169935026000033/si-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T20:10:17.763317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"267b44b702ede1137de394c31e0ca0f257c514ea","claim":"SHOULDER INNOVATIONS, INC. reported the first quarter ended March 31, 2026 results: revenue $16.7 million, net income $8.4 million. Guidance raised.","evidence_excerpt":"the shoulder surgical care market, today reported financial results for the first quarter ended March 31, 2026. First Quarter Financial Highlights • Generated net revenue of $16.7 million in the first quarter, a 65% increase over the first quarter of 2025 • Achieved gross margin of 77.7% for the first quarter compared to 76.9% for the first quarter of 2025 •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699350/000169935026000033/0001699350-26-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$16.7 million"},{"label":"Net income","value":"$8.4 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}